Reappraisal of Prognostic Impact of Tumor SUVmax by
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
pubmed:
27
1
2019
medline:
30
6
2019
entrez:
26
1
2019
Statut:
ppublish
Résumé
We previously reported that tumor standardized uptake value (SUVmax) by Data from 82 consecutive ICC patients, who underwent Tumor SUVmax was associated with tumor size (p = 0.002) and tumor number (p = 0.005), but not associated with T and N stage classified by American Joint Committee on Cancer-classification system, and other tumor factors. According to the tumor SUVmax cut-off values of 8.0 based on the minimum p value approach, actuarial 5-year overall survival (OS) rates in patients undergoing upfront surgery for ICC were significantly stratified at 54.7% versus 26.0% (low vs. high tumor SUVmax group, p = 0.008). The actuarial 3-year disease-free survival (DFS) rates were also significantly stratified at 41.0% versus 18.3% (p < 0.001). Multivariate Cox regression analyses revealed that tumor SUVmax retained its significance on OS (p = 0.039) as well as DFS (p < 0.001). Even in the era of multidisciplinary strategy, high tumor SUVmax still represents poor prognosis in patients undergoing surgery for ICC. These patients, therefore, would probably be required more effective strategies.
Sections du résumé
BACKGROUND
BACKGROUND
We previously reported that tumor standardized uptake value (SUVmax) by
METHODS
METHODS
Data from 82 consecutive ICC patients, who underwent
RESULTS
RESULTS
Tumor SUVmax was associated with tumor size (p = 0.002) and tumor number (p = 0.005), but not associated with T and N stage classified by American Joint Committee on Cancer-classification system, and other tumor factors. According to the tumor SUVmax cut-off values of 8.0 based on the minimum p value approach, actuarial 5-year overall survival (OS) rates in patients undergoing upfront surgery for ICC were significantly stratified at 54.7% versus 26.0% (low vs. high tumor SUVmax group, p = 0.008). The actuarial 3-year disease-free survival (DFS) rates were also significantly stratified at 41.0% versus 18.3% (p < 0.001). Multivariate Cox regression analyses revealed that tumor SUVmax retained its significance on OS (p = 0.039) as well as DFS (p < 0.001).
CONCLUSION
CONCLUSIONS
Even in the era of multidisciplinary strategy, high tumor SUVmax still represents poor prognosis in patients undergoing surgery for ICC. These patients, therefore, would probably be required more effective strategies.
Identifiants
pubmed: 30680501
doi: 10.1007/s00268-019-04917-z
pii: 10.1007/s00268-019-04917-z
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1323-1331Références
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Surgery. 2008 Jun;143(6):769-77
pubmed: 18549893
J Hepatobiliary Pancreat Sci. 2011 Jan;18(1):39-46
pubmed: 20503059
Ann Surg. 2010 Jul;252(1):107-14
pubmed: 20531002
Clin Nucl Med. 2014 Jan;39(1):1-7
pubmed: 24335565
J Hepatol. 2014 Jun;60(6):1268-89
pubmed: 24681130
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
Anticancer Res. 2014 May;34(5):2551-4
pubmed: 24778075
Clin Nucl Med. 2016 Jan;41(1):1-7
pubmed: 26402131
Cancer. 2016 Jan 1;122(1):61-70
pubmed: 26430782
Hepatol Res. 2016 Mar;46(5):372-90
pubmed: 26970231
World J Surg. 2016 Sep;40(9):2229-36
pubmed: 27255940
Liver Cancer. 2016 Oct;5(4):280-289
pubmed: 27781200
Cancer. 2017 Apr 15;123(8):1354-1362
pubmed: 27984655
Ann Surg Oncol. 2017 May;24(5):1351-1357
pubmed: 28108828
Cancer Discov. 2017 Jul;7(7):OF1
pubmed: 28572460
World J Surg. 2018 Mar;42(3):823-834
pubmed: 28905105
Ann Surg Oncol. 2018 Feb;25(2):542-549
pubmed: 29168098
World J Surg. 2018 Jun;42(6):1848-1856
pubmed: 29218465